Heart Disease, Diabetes Risk Appear Absent with Ziprasidone
Walsh, Nancy, Clinical Psychiatry News
NEW YORK -- Unlike other atypical antipsychotics, ziprasidone was not found to increase the risk for diabetes or cardiovascular disease in an analysis of data from the Clinical Antipsychotic Trials in Intervention Effectiveness study.
Results from CATIE indicated that patients with schizophrenia at baseline are at increased risk of coronary heart disease (CHD), compared with age- and sex-matched controls, according to Brian J. Cuffel, Ph.D., of Pfizer Inc.
CATIE included 1,493 patients with schizophrenia recruited from 57 clinical facilities in the United States. At baseline, fasting laboratory values were obtained and patients randomly assigned to treatment with …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: Heart Disease, Diabetes Risk Appear Absent with Ziprasidone.
Contributors: Walsh, Nancy - Author.
Magazine title: Clinical Psychiatry News.
Volume: 34.
Issue: 12
Publication date: December 2006.
Page number: 18.
© 2009 International Medical News Group.
COPYRIGHT 2006 Gale Group.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset